TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets. Newer biologics that offer alternative treatment options (i.e., Takeda’s Entyvio and Janssen’s Stelara) as well as the increasing penetration of biosimilar infliximab (e.g., Pfizer’s Inflectra) continue to expand the UC/CD treatment landscapes. The launch of Xeljanz in 2018, the first oral agent and first JAK inhibitor in UC, will further shift UC market dynamics. Additionally, the arrival of emerging agents—some with novel MOAs—including Gilead/Galapagos’s filgotinib, Celgene’s ozanimod, and Roche’s etrolizumab, and the increasing physician prescribing of biosimilars will fuel competition and add to pricing pressure. Emerging therapies seeking favorable uptake in UC and/or CD will face a growing number of market access challenges.
Geography: United States.
Primary Research: Survey of ~100 U.S. gastroenterologists and ~30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Key Drugs Covered: Remicade, Humira, Biosimilar infliximab, Simponi, Cimzia, Entyvio, Stelara, Xeljanz.
Content highlights: Reimbursement and contracting; access and prescribing; special topics; opportunities and challenges for emerging therapies.
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.